PTMA, prothymosin alpha, 5757

N. diseases: 71; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.320 Biomarker disease BEFREE The present study was designed to investigate ProTα expression in resected human non-small cell lung cancer to define the clinicopathological associations of ProTα-positive lung cancer. 31105795 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.320 AlteredExpression disease BEFREE The PTalpha and c-myc mRNA levels in lung cancer tissues were higher than those in normal lung tissues; however, the PTalpha mRNA levels did not correlate with the stage or pathological subtype of the lung cancer and there was no correlation between the expression of PTalpha and c-myc. 11759895 2001
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.320 Therapeutic disease CTD_human Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice. 10822126 2000
CUI: C0035412
Disease: Rhabdomyosarcoma
Rhabdomyosarcoma 		0.310 AlteredExpression disease BEFREE Prothymosin alpha (PTMA), and translocase of inner mitochondrial membrane 10 (Tim10), two genes not previously implicated in RMS, showed reduced expression during differentiation. 16669873 2006
CUI: C0035412
Disease: Rhabdomyosarcoma
Rhabdomyosarcoma 		0.310 Biomarker disease CTD_human Prothymosin alpha (PTMA), and translocase of inner mitochondrial membrane 10 (Tim10), two genes not previously implicated in RMS, showed reduced expression during differentiation. 16669873 2006
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.300 Therapeutic disease CTD_human Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. 15885234 2005
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.300 Therapeutic disease CTD_human Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. 15885234 2005
CUI: C0001430
Disease: Adenoma
Adenoma 		0.300 Therapeutic group CTD_human Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice. 10822126 2000
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms 		0.300 Therapeutic group CTD_human Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice. 10822126 2000
CUI: C0205646
Disease: Adenoma, Basal Cell
Adenoma, Basal Cell 		0.300 Therapeutic disease CTD_human Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice. 10822126 2000
CUI: C0205647
Disease: Follicular adenoma
Follicular adenoma 		0.300 Therapeutic disease CTD_human Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice. 10822126 2000
CUI: C0205648
Disease: Adenoma, Microcystic
Adenoma, Microcystic 		0.300 Therapeutic disease CTD_human Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice. 10822126 2000
CUI: C0205649
Disease: Adenoma, Monomorphic
Adenoma, Monomorphic 		0.300 Therapeutic disease CTD_human Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice. 10822126 2000
CUI: C0205650
Disease: Papillary adenoma
Papillary adenoma 		0.300 Therapeutic disease CTD_human Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice. 10822126 2000
CUI: C0205651
Disease: Adenoma, Trabecular
Adenoma, Trabecular 		0.300 Therapeutic disease CTD_human Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice. 10822126 2000
CUI: C0023508
Disease: White Blood Cell Count procedure
White Blood Cell Count procedure 		0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.060 Biomarker group BEFREE Our data support that nuclear PTMA protein serves as a tumor suppressor in bladder cancer through upregulating PTEN and orchestrating TRIM21 for the regulation of Nrf2 signaling. 30719818 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.060 AlteredExpression group BEFREE The PTMA expression was up-regulated gradually along the progression of ESCC, and the PTMA expression ratio between tumor and adjacent normal tissue was significantly increased along with the progression. 30988666 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.060 Biomarker group BEFREE Immunohistochemical staining of ProTα was performed using tumor sample slides from 149 patients with non-small cell lung cancer, who underwent surgical resection. 31105795 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.060 AlteredExpression group BEFREE However, positive expression of PTMA and PTMA was associated with tumor size, TNM stage, lymph node metastasis, locally invasive growth, and treatment with radical resection in patients with SCC/ASC and AC (P<0.05). 29541218 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.060 AlteredExpression group BEFREE β-Catenin and prothymosin alpha (PTMA) are overexpressed in HCC and other tumors. 26517516 2015
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.060 AlteredExpression group BEFREE There was a tendency that higher prothymosin alpha transcripts levels in the tumor samples from younger patients (<1year.) when compared to the older group (>1 year.)(P=0.0845). 11403924 2001
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 Biomarker group BEFREE Prothymosin α (ProTα) is a nuclear protein that serves a role in oncogenesis, by promoting proliferation and inhibiting apoptosis in various malignancies. 31105795 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 Biomarker group BEFREE We, therefore, suggest that proTα, and likely proTα(100-109), act as alarmins, being important immune mediators as well as biomarkers, and could eventually become targets for new therapeutic/diagnostic approaches in immune-related diseases like cancer, inflammation, and sepsis. 28521686 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 AlteredExpression group BEFREE Therefore PTMA siRNA may have potential applications as an adjuvant in cancer chemotherapy. 22059741 2011